GlassScriptPhysician profile
Andrew J Long
NPI 1558554808
$2,035.32
in general payments reported to CMS, 2019-2025
27 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.90 · 2020: $76.53 · 2021: $96.88 · 2022: $325 · 2023: $306 · 2024: $543 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.60 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.48 | 2020-2024 | Ofev, Jardiance |
| Novo Nordisk INC | $140.47 | 2022-2025 | Wegovy, Saxenda, Ozempic |
| Teleflex LLC | $111.43 | 2025 | Deflux Metal Needle |
| Lilly USA, LLC | $105.72 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $103.92 | 2020-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $95.78 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $84.80 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Abbott Laboratories | $84.68 | 2025 | Diamondback Peripheral, Esprit |
| Bayer Healthcare Pharmaceuticals INC. | $77.67 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $56.51 | 2019-2021 | |
| Alkermes, INC. | $55.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $52.28 | 2023-2025 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $49.98 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $37.27 | 2020-2023 | Camzyos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.02 | 2022-2024 | Arexvy |
| Rgh Enterprises LLC | $27.00 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.72 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $24.59 | 2025 | |
| Indivior INC. | $23.18 | 2024 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $22.99 | 2025 | Austedo Xr |
| Radius Health, INC. | $20.21 | 2024 | Tymlos |
| Astellas Pharma US INC | $18.36 | 2024 | Veozah |
| Insulet Corporation | $16.98 | 2025 | Omnipod |
| Antares Pharma, INC. | $16.75 | 2023 | Tlando, Xyosted, Nocdurna |
| Mylan Specialty L.P. | $16.22 | 2022 | |
| Merck Sharp & Dohme LLC | $16.12 | 2024 | Proquad, Vaxelis, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.